Advertisement

ASCO GI 2023

New First-Line Option for Metastatic Pancreatic Duct Cancer

Jan 27, 2023

REFERENCES & ADDITIONAL READING

  1. Wainberg ZA, et al. NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). Late-breaking abstract 661, ASCO GI 2023, 19–21 January, San Francisco, CA, USA.

Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement